VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 300 filers reported holding VALEANT PHARMACEUTICALS INTL in Q3 2017. The put-call ratio across all filers is 2.07 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $2,948,000 | -21.5% | 126,736 | -46.3% | 0.01% | -23.5% |
| Q1 2018 | $3,755,000 | +16.7% | 236,036 | +53.3% | 0.02% | +13.3% |
| Q4 2017 | $3,219,000 | +925.2% | 153,933 | +601.8% | 0.02% | +1400.0% |
| Q3 2017 | $314,000 | -10.5% | 21,933 | +8.6% | 0.00% | -50.0% |
| Q2 2017 | $351,000 | +56.0% | 20,195 | -1.2% | 0.00% | +100.0% |
| Q1 2017 | $225,000 | -94.6% | 20,432 | -87.1% | 0.00% | -96.7% |
| Q1 2016 | $4,156,000 | -82.8% | 157,900 | -33.8% | 0.03% | -82.1% |
| Q4 2015 | $24,143,000 | +58.6% | 238,600 | +178.4% | 0.17% | +38.8% |
| Q3 2015 | $15,226,000 | -19.7% | 85,700 | +0.4% | 0.12% | -25.3% |
| Q2 2015 | $18,953,000 | -1.4% | 85,400 | -12.2% | 0.16% | +8.0% |
| Q1 2015 | $19,223,000 | +170.7% | 97,300 | +80.5% | 0.15% | +138.1% |
| Q1 2014 | $7,102,000 | +65.7% | 53,900 | +56.7% | 0.06% | +53.7% |
| Q4 2013 | $4,287,000 | +42.8% | 34,400 | +3.9% | 0.04% | +13.9% |
| Q2 2013 | $3,002,000 | – | 33,100 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chou Associates Management | 1,648,992 | $38,323,000 | 14.52% |
| Paulson & Co. | 20,839,035 | $484,299,000 | 9.89% |
| MILLER VALUE PARTNERS, LLC | 4,999,064 | $116,178,000 | 4.34% |
| GoldenTree Asset Management | 1,140,205 | $26,498,000 | 4.21% |
| Pomelo Capital LLC | 1,760,000 | $40,902,000 | 4.00% |
| Bruce & Co., Inc. | 860,000 | $19,986,000 | 3.98% |
| ValueAct Holdings | 18,033,149 | $419,090,000 | 3.79% |
| Stanley Capital Management, LLC | 318,400 | $7,400,000 | 3.25% |
| Kazazian Asset Management, LLC | 134,784 | $3,132,000 | 2.87% |
| Phoenix Investment Adviser LLC | 58,400 | $1,357,000 | 2.48% |